GMAT Question of the Day - Daily to your Mailbox; hard ones only

It is currently 16 Oct 2019, 20:26

Close

GMAT Club Daily Prep

Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track
Your Progress

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.

Close

Request Expert Reply

Confirm Cancel

Most of the Pharmaceutical Companies feel hesitant in publishing infor

  new topic post reply Question banks Downloads My Bookmarks Reviews Important topics  
Author Message
TAGS:

Hide Tags

Find Similar Topics 
Verbal Forum Moderator
avatar
Joined: 15 Apr 2013
Posts: 178
Location: India
Concentration: General Management, Marketing
GMAT Date: 11-23-2015
GPA: 3.6
WE: Science (Other)
GMAT ToolKit User Reviews Badge
Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

Show Tags

New post 05 Feb 2014, 03:20
4
00:00
A
B
C
D
E

Difficulty:

  45% (medium)

Question Stats:

64% (01:57) correct 36% (02:03) wrong based on 490 sessions

HideShow timer Statistics

Most of the Pharmaceutical Companies feel hesitant in publishing information about clinical trials at free online databases, asserting doing this would reveal their product “Business Strategy” to competitors. Indeed, invaluable confidential information which otherwise could not be accessed by competitors, offers serious threat to a Pharmaceutical Companies. Therefore the policy of publication of clinical trial results at free online databases should be withdrawn.

Which of the following (if true) would most likely weaken the conclusion?


(A) If Business Strategy is often build well before the planning of clinical trial
(B) Competitors have access to the online databases
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval
(D) Clinical trial conduct often differ from company to company
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success
Magoosh GMAT Instructor
User avatar
G
Joined: 28 Dec 2011
Posts: 4472
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

Show Tags

New post 06 Feb 2014, 14:16
vikasbansal227 wrote:
Most of the Pharmaceutical Companies feel hesitant in publishing information about clinical trials at free online databases, asserting doing this would reveal their product “Business Strategy” to competitors. Indeed, invaluable confidential information which otherwise could not be accessed by competitors, offers serious threat to a Pharmaceutical Companies. Therefore the policy of publication of clinical trial results at free online databases should be withdrawn.
Which of the following (if true) would most likely weaken the conclusion?
(A) If Business Strategy is often build well before the planning of clinical trial
(B) Competitors have access to the online databases
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval
(D) Clinical trial conduct often differ from company to company
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success

Dear vikasbansal227,
I'm happy to respond. :-)

This question is a complete disaster. Among the flaws
(1) idiom mistake: "hesitant in publishing" should be "hesitant to publish"
(2) it seems "Pharmaceutical Companies" is construed as plural; why it is capitalized is anyone's guess, but using the singular article before this noun makes no sense: "threat to a Pharmaceutical Companies
(3) the "if" at the beginning of choice (A) makes no sense

On the GMAT, and in all high quality test prep sources, the quality of the language in a GMAT CR or RC practice problem adheres to the high standards held in GMAT SC.

Those are my thoughts.
Mike
_________________
Mike McGarry
Magoosh Test Prep


Education is not the filling of a pail, but the lighting of a fire. — William Butler Yeats (1865 – 1939)
Manager
Manager
avatar
Status: Oh GMAT ! I give you one more shot :)
Joined: 14 Feb 2013
Posts: 75
Location: United States (MI)
Concentration: General Management, Technology
GMAT 1: 580 Q44 V28
GMAT 2: 690 Q49 V34
GPA: 3.5
WE: Information Technology (Computer Software)
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

Show Tags

New post 07 Feb 2014, 10:16
1
vikasbansal227 wrote:
Most of the Pharmaceutical Companies feel hesitant in publishing information about clinical trials at free online databases, asserting doing this would reveal their product “Business Strategy” to competitors. Indeed, invaluable confidential information which otherwise could not be accessed by competitors, offers serious threat to a Pharmaceutical Companies. Therefore the policy of publication of clinical trial results at free online databases should be withdrawn.
Which of the following (if true) would most likely weaken the conclusion?
(A) If Business Strategy is often build well before the planning of clinical trial
(B) Competitors have access to the online databases
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval
(D) Clinical trial conduct often differ from company to company
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success


Ignoring the obvious grammatical issues with the questions and options, the answer must be C

(A) Business Strategy is often build well before the planning of clinical trial - This is a strengthener. As the strategies are made well before clinical trial, in case rivals copy the secrets then there won't be any time to alter the strategy to counter it.
(B) Competitors have access to the online databases - Another strengthener, if competitors have access to the data then they can copy the product.
(C) Pharmaceutical companies publish the clinical trial information at online databases after product approval - This is a weakener, if the product is approved before the trial data is published then there is no chance for competitors to copy the product.
(D) Clinical trial conduct often differ from company to company - Has no impact on the conclusion, even though the trial differs still competitors can copy the trial process of a company.
(E) Creation of Business Strategy and Clinical Trials conduct are most important factors in product success - Just a general statement, has no impact on the conclusion.
_________________
Life is a highway
I wanna ride it all night long
Intern
Intern
avatar
B
Joined: 18 Jul 2018
Posts: 35
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor  [#permalink]

Show Tags

New post 23 Oct 2018, 02:35
I did not understood the question.Can someone please explain?

Posted from my mobile device
GMAT Club Bot
Re: Most of the Pharmaceutical Companies feel hesitant in publishing infor   [#permalink] 23 Oct 2018, 02:35
Display posts from previous: Sort by

Most of the Pharmaceutical Companies feel hesitant in publishing infor

  new topic post reply Question banks Downloads My Bookmarks Reviews Important topics  





Powered by phpBB © phpBB Group | Emoji artwork provided by EmojiOne